202 related articles for article (PubMed ID: 29795429)
1. Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract.
Ganetsky A; Frey NV; Hexner EO; Loren AW; Gill SI; Luger SM; Mangan JK; Martin ME; Babushok DV; Drobyski WR; Smith J; Timlin C; Freyer CW; Stadtmauer EA; Porter DL
Bone Marrow Transplant; 2019 Feb; 54(2):212-217. PubMed ID: 29795429
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
Yucebay F; Matthews C; Puto M; Li J; William B; Jaglowski SM; Penza SL; Vasu S; Benson DM; Andritsos LA; Devine SM; Efebera YA; Roddy JVF
Leuk Lymphoma; 2019 Sep; 60(9):2223-2229. PubMed ID: 30764681
[TBL] [Abstract][Full Text] [Related]
3. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
Kennedy GA; Varelias A; Vuckovic S; Le Texier L; Gartlan KH; Zhang P; Thomas G; Anderson L; Boyle G; Cloonan N; Leach J; Sturgeon E; Avery J; Olver SD; Lor M; Misra AK; Hutchins C; Morton AJ; Durrant ST; Subramoniapillai E; Butler JP; Curley CI; MacDonald KPA; Tey SK; Hill GR
Lancet Oncol; 2014 Dec; 15(13):1451-1459. PubMed ID: 25456364
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab for steroid refractory acute graft-versus-host disease.
Roddy JV; Haverkos BM; McBride A; Leininger KM; Jaglowski S; Penza S; Klisovic R; Blum W; Vasu S; Hofmeister CC; Benson DM; Andritsos LA; Devine SM; Efebera YA
Leuk Lymphoma; 2016; 57(1):81-5. PubMed ID: 26140610
[TBL] [Abstract][Full Text] [Related]
5. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-
Drobyski WR; Szabo A; Zhu F; Keever-Taylor C; Hebert KM; Dunn R; Yim S; Johnson B; D'Souza A; Eapen M; Fenske TS; Hari P; Hamadani M; Horowitz MM; Rizzo JD; Saber W; Shah N; Shaw B; Pasquini M
Haematologica; 2018 Apr; 103(4):717-727. PubMed ID: 29351985
[TBL] [Abstract][Full Text] [Related]
7. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Utility of Endoscopy and Biopsy in Suspected Acute Gastrointestinal Graft-versus-Host Disease after Hematopoietic Progenitor Cell Transplantation.
Scott AP; Tey SK; Butler J; Kennedy GA
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1294-1298. PubMed ID: 29410342
[TBL] [Abstract][Full Text] [Related]
9. Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review.
Fløisand Y; Lazarevic VL; Maertens J; Mattsson J; Shah NN; Zachée P; Taylor A; Akbari M; Quadri S; Parfionovas A; Chen YB
Biol Blood Marrow Transplant; 2019 Apr; 25(4):720-727. PubMed ID: 30468919
[TBL] [Abstract][Full Text] [Related]
10. Outcome of gastrointestinal graft-versus-host disease according to the treatment response.
Tamaki M; Nakasone H; Misaki Y; Yoshimura K; Gomyo A; Hayakawa J; Kusuda M; Akahoshi Y; Ishihara Y; Kawamura K; Tanihara A; Sato M; Terasako-Saito K; Kameda K; Wada H; Kikuchi M; Kimura SI; Kako S; Kanda Y
Ann Hematol; 2018 Oct; 97(10):1951-1960. PubMed ID: 29860563
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab for the treatment of steroid refractory graft-versus-host disease.
Drobyski WR; Pasquini M; Kovatovic K; Palmer J; Douglas Rizzo J; Saad A; Saber W; Hari P
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1862-8. PubMed ID: 21745454
[TBL] [Abstract][Full Text] [Related]
12. Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.
Sung AD; Hassan S; Cardona DM; Wild D; Nichols KR; Mehdikhani H; Balmadrid B; Detweiler CJ; Shealy M; Cirrincione C; Li Z; Poleski M; Dalton TE; Siamakpour-Reihani S; Chao NJ; Sullivan KM
Biol Blood Marrow Transplant; 2018 Apr; 24(4):734-740. PubMed ID: 29246821
[TBL] [Abstract][Full Text] [Related]
13. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
15. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of intra-arterial steroid infusions in patients with steroid-resistant gastrointestinal acute graft-versus-host disease.
Nishimoto M; Koh H; Hirose A; Nakamae M; Nakane T; Hayashi Y; Okamura H; Yoshimura T; Koh S; Nanno S; Nakashima Y; Takeshita T; Yamamoto A; Sakai Y; Nishida N; Matsuoka T; Miki Y; Hino M; Nakamae H
Exp Hematol; 2015 Dec; 43(12):995-1000. PubMed ID: 26303639
[TBL] [Abstract][Full Text] [Related]
17. [Humanized anti-CD25 monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation].
Wu YX; Wu DP; Ma X; Jiang SS; Hou MJ; Jing YT; Liu B; Li Q; Wang X; Wu YB; Hu XH
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):755-761. PubMed ID: 38049320
[No Abstract] [Full Text] [Related]
18. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
[TBL] [Abstract][Full Text] [Related]
19. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
MacMillan ML; Weisdorf DJ; Wagner JE; DeFor TE; Burns LJ; Ramsay NK; Davies SM; Blazar BR
Biol Blood Marrow Transplant; 2002; 8(7):387-94. PubMed ID: 12171485
[TBL] [Abstract][Full Text] [Related]
20. Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease.
Fløisand Y; Lundin KEA; Lazarevic V; Kristiansen JD; Osnes LTN; Tjønnfjord GE; Reims HM; Gedde-Dahl T
Biol Blood Marrow Transplant; 2017 Jan; 23(1):172-175. PubMed ID: 27777142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
